Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/20694

Title: Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index
Authors: de Bock, Laura
Fraussen, Judith
Villar, Luisa M.
Alvarez-Cermeno, Jose C.
Van Wijmeersch, Bart
van Pesch, Vincent
Stinissen, Piet
Somers, Veerle
Issue Date: 2015
Citation: EUROPEAN JOURNAL OF NEUROLOGY 23(4), p. 722-728
Abstract: Background and purpose: Sperm-associated antigen 16 (SPAG16), a sperm protein which is upregulated in reactive astrocytes in multiple sclerosis (MS) lesions, has recently been identified as a novel autoantibody target in MS. The aim of this study was to investigate whether anti-SPAG16 antibody levels differ between MS subtypes (relapsing remitting, RR; primary or secondary progressive, PP, SP) and whether antibody positivity is associated with clinical characteristics. Methods: Plasma anti-SPAG16 antibody levels were determined by recombinant protein enzyme-linked immunosorbent assay (ELISA) in 374 MS patients (274 RRMS, 39 SPMS and 61 PPMS) and 106 healthy controls. Results: Significantly elevated anti-SPAG16 antibodies were found in 22% of MS patients with 93% specificity. Anti-SPAG16 seropositivity was associated with an increased Expanded Disability Status Scale (EDSS) in overall MS. A higher proportion of PPMS patients showed anti-SPAG16 antibody reactivity (34%) compared to RRMS (19%) and SPMS (26%), and presented with higher anti-SPAG16 antibody levels. Seropositive PPMS patients had a significantly increased progression index compared to seronegative patients. Conclusions: Anti-SPAG16 antibodies are associated with an increased EDSS in overall MS, indicating that they are linked to a worse MS disease outcome. Moreover, the presence of anti-SPAG16 antibodies may be a biomarker for a more severe disease in PPMS patients, as indicated by an increased progression index.
Notes: Correspondence: V. Somers, Hasselt University, Biomedical Research Institute, Martelarenlaan 42, B-3500 Hasselt, Belgium (tel.: +32- 11269202; fax: +32-11269299; e-mail: veerle.somers@uhasselt.be)
URI: http://hdl.handle.net/1942/20694
DOI: 10.1111/ene.12925
ISI #: 000372972300013
ISSN: 1351-5101
Category: A1
Type: Journal Contribution
Validation: ecoom, 2017
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
published version207.06 kBAdobe PDF
Peer-reviewed author version218.69 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.